Thus, the poor efficacy of RTKIs in TNBC may be due to the low occurrence of activating EGFR mutations in TNBC (3–11%)32, 33 as compared to non-small cell lung cancers (10–35%)34, 35. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.